Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease.

Haydeh Payami* [1,2], Timothy R Sampson [2,3], Charles F Murchison [1,2,4]

[1] Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA
[2] Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA
[3] Department of Cell Biology, Emory University, Atlanta, GA, 30329, USA
[4] Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 35233, USA

***Senior and Corresponding author:**
Haydeh Payami, PhD
University of Alabama at Birmingham, Room 429, Civitan International Research Center, 1719 6th Ave S, Birmingham, AL 35233
Phone: 205-994-1909
Email: haydehpayami@uabmc.edu

Running title: Microbiome-based biomarkers

Word count: Abstract 125. Introduction 448. Method 995. Results 610. Discussion 867. 32 references. 2 Tables. 3 Figures.

Abstract

We address an unmet challenge in Parkinson's disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. We present the gut microbiome as a target for treatment and introduce microbiome-based biomarkers to guide personalized treatments. We show that not all persons with PD have a dysbiotic microbiome, and not all dysbiotic PD microbiomes have the same features. We have developed an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual's dysbiotic features. We demonstrate the method for PD. The concept, and the method, is generalizable for any disease with a microbiome component.

Introduction

Parkinson's disease (PD) is the fastest growing neurologic disease in the world [1]. PD is a progressively debilitating disease [2]. The earliest manifestations are often constipation, sleep disorder, and hyposmia, leading to the cardinal movement disorders, and as disease progresses, most patients develop psychosis and dementia. Treatments are symptomatic. There have been many clinical trials for disease modifying treatment aimed at stopping disease progression, and all have failed (clinicaltrials.gov). PD is a highly heterogenous disease. One treatment will not work for all patients. Biomarkers to guide selection of the right patients for the right drug has been a high-priority, unmet need.

It has long been known that constipation, inflammation in the gut, and permeable gut membrane are common in PD and precede motor signs [2]. Recent studies suggest some cases of PD start in the gut and spread to the brain, and in rodent models, PD pathologies are observed to spread from gut to brain [3-7]. The gut origin raised the possibility that the gut microbiome could be involved in the brain-gut-axis pathology of PD. A healthy gut microbiome controls metabolism of drugs, toxicants and food, synthesis of vitamins and neurotransmitters, keeps the lining of the gut intact, protects against pathogens, maintains the proper functioning of the immune and nervous systems, and modulates brain-gut communication [8].

It is becoming increasing clear that the gut microbiome is severely dysbiotic in PD [9-11], with features that could directly affect initiation and progression of PD. Dysbiotic features of PD microbiome are relevant to multiple PD mechanisms [9], including increased abundance of pathogens and immunogens, decreased production of neuroactive molecules (dopamine, serotonin, glutamate and GABA), reduced capacity to degrade plant-based fiber which leads to short chain fatty acids deficiency, increased inflammation and compromised gut barrier, and elevated *E. coli* and curli. Curli is a bacterial amyloid produced by *E.coli* which, in mice, induces alpha-synuclein aggregation, the hallmark of PD pathology [12,13]. Data from genetic and toxicant-induced models of PD also suggest gut microbiome can trigger or contribute to various PD pathologies and the manifestation of motor and non-motor phenotypes [14-17], and that altering the microbiome via fecal microbiome transplantation (FMT)[18,19], antibiotics treatments[20-23], or high fiber diet[24], each to some extent can reduce alpha-synuclein pathology, inflammation, and motor and non-motor dysfunction.

The gut microbiome is an emerging target for PD therapies [25,26]. Results of early clinical trials with fiber supplementation [27] and FMT [28-31] are promising. Next-generation targeted therapeutics are forthcoming. Here, we show that not all PD patients have a dysbiotic microbiome and not all dysbiotic microbiomes have the same features. We introduce microbiome-based biomarkers to guide patient selection for clinical trials, and upon success, as companion diagnostic for personalized treatment.

The Method

Overview

The overview of the method is shown in **Figure 1**. The concept and method are generalizable to any disorder with a microbiome component, here, we fcus on PD. The method requires a metagenomics reference dataset from older adults without PD. Non-PD individuals should be from the same population as the patients to be studied or treated (such reference datasets will soon be available for several populations). We select features of interest as potential targets for treatment. Features can be a single gene or metabolite, a species, a cluster of related species, or multiple polymicrobial clusters that are being targeted for treatment. We then calculate the mean relative abundance and confidence intervals (CI) of the features in the metagenomics dataset of older adults without PD. We have now created the reference dataset. We define

dysbiosis by setting thresholds for relative abundances in reference dataset (e.g., outside 95% CI). Patients can now be screened for dysbiotic features, which entails obtaining a stool sample, metagenomic sequencing and comparing the relative abundance of the features in the patient to the reference dataset and the thresholds that define dysbiosis.

Foundation of the method

We previously conducted a large-scale high-resolution metagenomic analysis, where we mapped the dysbiotic features of PD microbiome [9]. Results were published and all data and protocols are open access without restriction (see Data Availability). The dataset is composed of deep-shotgun next-generation metagenome sequences of microbial DNA, extracted from stool samples of 490 individuals with PD and 234 neurologically healthy controls (NHC). We conducted a metagenome-wide association study (MWAS) and identified species, genes and pathways that are depleted or overly abundant in PD. We also conducted correlations network analysis (using SparCC) and identified polymicrobial clusters of species whose abundances grow or shrink together [9]. The visual of PD microbiome network and its clusters resembles and thus is called Fireworks (**Figure 2**).

The concept

The published study [9] was microbiome-centric, i.e., we identified dysbiotic features in aggregates of patients as compared to NHC. We now turn the approach around and make it individual-centric, i.e., what does the microbiome in a given patient look like? Is the microbiome dysbiotic in every PD patient? Are all dysbiotic features present together, or are some features present in a subset of patients, and if so, what percentage of patients has a given dysbiotic feature? The answers to these questions are fundamental to any microbiome-based therapeutic. To answer these questions, we had to (a) select features of interest that could potentially be a target of treatment and (b) create an operational definition of dysbiosis. The concept is generalizable, and the method, both feature selection and definition of dysbiosis, can be modified to accommodate study design.

Features of PD gut microbiome

122 For feature selection, we used the data reported in Wallen et al [9]. We selected species that were
123 significantly associated with PD (i.e., their abundance was elevated or reduced in PD) [9], plus the
124 cluster of rare opportunistic pathogens, which were too rare to be tested individually, but form a
125 polymicrobial cluster that was shown in two independent datasets to be elevated in PD [9,32]. We
126 grouped the selected PD-associated species into six features based on the correlation in their
127 abundances (|r|>0.2, P<0.05) and taxonomic relatedness (members of same genus). The six
128 dysbiotic features (**Table 1, Figure 2**) are as follows: (1) the cluster of opportunistic pathogens
129 (elevated in PD), (2) species of *Bifidobacteria* (elevated in PD), (3) species of *Lactobacillus*
130 (elevated in PD), (4) *Streptococcus* and *Actinomyces* species that are elevated in PD, (5) *E. coli*
131 and *Klebsiella species* that are elevated in PD, and (6) fiber-degrading bacteria (reduced in PD).
132 There is more to the dysbiosis of PD gut than these six features [9]. The features can be
133 redefined to accommodate the aims of the investigation. Here, we strived for a balance between
134 minimizing complexity while capturing the most robust and biologically relevant features. The
135 aim was to demonstrate the method behind microbiome-based biomarkers.
136
137 **Definition of dysbiotic and non-dysbiotic**
138
139 We needed a working definition of dysbiotic. First step is to optimize patient selection for clinical
140 trials. To that end, we set high thresholds for defining dysbiosis in order to maximize the odds
141 that the patient being enrolled is an optimal candidate. These thresholds can be changed to
142 accommodate study design, or relaxed when a drug is approved, and the biomarkers become
143 companion diagnostics for personalized treatment.
144
145 For each feature, and per person, we calculated total relative abundance of each feature by
146 summing the relative abundances of the species within it. We then calculated the mean relative
147 abundance and its 95% CI in NHC (reference dataset). Next, we turned to individual-level PD
148 data. Considering each feature separately, we called a PD person's metagenome dysbiotic if the
149 relative abundance of the feature was outside the 95% CI of NHC. For features that are
150 elevated in PD in aggregate data, a PD individual's gut was called dysbiotic if the relative
151 abundance of the feature in that person was greater than the upper bound of 95% CI of NHC.
152 For the feature that is reduced in PD, a PD individual's microbiome was called dysbiotic if the
153 relative abundance of the feature in that person was less than the lower bound of 95% CI of
154 NHC (**Table 2**).
155

A key question was whether all individuals with PD have a dysbiotic gut microbiome. To answer this question, we needed an operational definition of non-dysbiotic. We defined non-dysbiotic per feature as being well within the norm of NHC range, i.e., below the mean of NHC if the feature is elevated in PD, and above the mean if a feature is reduced in PD. When considering all six features, a PD person was designated as not having a dysbiotic microbiome only if their relative abundance for the five elevated features were all at or below the mean of NHC, and their relative abundance for reduced fiber degrading feature was at or greater than the mean in NHC.

Results

Not all PD metagenomes are dysbiotic, and not all dysbiotic microbiomes have the same features.

Among 490 individuals with PD studied, 392 (80%) had at least one dysbiotic feature (**Figure 3a**). 98 (20%) did not have any dysbiotic feature defined as being outside the 95% CI of NHC. Using the more cautious definition of non-dysbiotic, i.e. elevated features being at or below the NHC mean and reduced features at or above the NHC mean, 76 (16%) of PD microbiomes were not dysbiotic. The patients without a dysbiotic microbiome can be identified and excluded from microbiome-based therapeutics; doing so will boost power and odds of success of clinical trials, and in clinical setting, will spare these patients unnecessary trial and error in finding the right treatment.

Severe reduction in fiber-degrading bacteria was seen in 333 of 490 of PD patients (68%) (**Figure 3a**). Among the 333 low fiber-degraders, only 96 had no other dysbiotic features (**Figure 3b**), hence 71% (=(333-96)/333) of patients with low fiber-degraders had high levels of at least one other dysbiotic feature. Thus, while deficiency of fiber degraders is very common, only 20% (=96/490) of PD patients had low fiber-degraders as their sole feature. This suggests that while fiber treatment would be beneficial for majority of patients, a subset would stand to benefit the most from fiber, while others may need treatment for their other dysbiotic features as well.

Features that are elevated in PD were found in subsets of patients: high levels of opportunistic pathogens was detected in 66 (13%) of the 490 PD, *Bifidobacterium* in 161 (33%), *Lactobacillus*

190 in 103 (21%), *Streptococcus* and *Actinomyces* in 94 (19%), and *E. coli* and *Klebsiella* in 86
191 (18%). To demonstrate utility of the biomarker, consider *E. coli* which has been linked to
192 pathobiology of PD. *E. coli* encodes curli, an amyloid that induces alpha-synuclein aggregation
193 in mice [12,13]. Alpha-synuclein aggregation is a pathogenic hallmark of PD. Moreover, *E. coli* and
194 genes that encode and regulate curli production are elevated in PD gut [9]. Should a drug be
195 developed against *E. coli* or curli, it will likely have a far better odds of success in clinical trial if
196 patients were chosen from the 18% that have high levels of *E. coli* and curli.
197
198 There is some overlap across the groups shown in **Figure 3a**, because these features are not
199 mutually exclusive. For example, as shown in **Figure 3b**, among the 66 patients with high
200 opportunistic pathogens, 33 (50%) also had high *Bifidobacteria*, 15 (23%) had high
201 *Lactobacillus*, 18 (27%) had high *Streptococcus* and *Actinomyces*, 13 (20%) had *E. coli* and
202 *Klebsiella*, and 57 (86%) had low fiber degraders. These data suggest that at the present time,
203 with fiber and FMT being the only microbiome-based treatments, the most rational option for
204 treating the patients who have a severely dysbiotic microbiome is cleansing the microbiome with
205 antibiotics followed by FMT, excluding those without dysbiosis and those with only low fiber-
206 degraders. We are not advocating for FMT or any treatment modality per se, rather, pointing out
207 the utility of biomarkers in designing a study as well as choosing the patients to study and treat.
208
209 **Application of the biomarker tool**
210
211 Defining the features of interest and setting abundance thresholds to define dysbiotic/non-
212 dysbiotic in a healthy population will constitute the reference dataset for this biomarker tool. To
213 determine the composition of the metagenome of a patient will entail obtaining a stool sample,
214 DNA extraction, sequencing, bioinformatic processing and taxonomic assignment of sequences,
215 and calculating relative abundances of the microbial features. The patient's relative abundances
216 for the features of interest are then compared to the reference dataset to determine if they are
217 dysbiotic (**Figure 1**).
218

219 Discussion

220
221 Here, we introduced a microbiome-based biomarker tool to guide patient selection for clinical
222 trials and to serve as companion diagnostic for personalized treatments. With this tool, we can
223 "see" if and what is dysbiotic in an individual and act accordingly. The method is applicable for

224 any patient at any stage of disease. The tool can be easily modified (by redefining features and
225 adjusting thresholds) as the field advances, and to meet varying needs of different studies.
226 Here, we demonstrated the development and the potential utility of the tool for identifying
227 subtypes of PD based on their microbiome features. The concept is generalizable to any
228 disease with a microbiome component.
229
230 Treating a dysbiotic microbiome can potentially be disease modifying, which has been an
231 elusive goal in PD field. Functional inference of human data and experiments in mice indicate
232 dysbiotic features of PD microbiome contribute to several disease mechanisms, including alpha-
233 synuclein aggregation which is at the core of PD pathology, disrupted neuro-signaling, and
234 inflammation [9,13,14]. It is therefore reasonable to work towards microbiome-based therapies that
235 could halt disease progression. As we learn which features are causal and which result from
236 disease (an active area of research), microbiome-based biomarkers will be useful for identifying
237 pathogenic dysbiosis early to prevent disease before onset.
238
239 Microbiome-based treatments under consideration for PD include prebiotics (e.g., fiber
240 supplements), probiotics (beneficial bacteria packaged and marketed direct to consumer), FMT,
241 and next generation therapeutics that are targeted to a specific feature (e.g., small molecules,
242 phage, CRSPR-Cas9). The microbiome-based biomarkers described here can serve as
243 companion diagnostic for all treatment modalities. Take fiber supplementation for example,
244 which is safe and likely beneficial for everyone. We show here that indeed, the majority of PD
245 patients have severely depleted levels of fiber-degrading bacteria. Increasing fiber intake is
246 effectively feeding these bacteria and causing them to grow and multiply, and it has shown
247 promise in an early clinical trial with newly diagnosed PD patients [27]. The value of coupling
248 biomarkers with fiber treatment is in identifying patients who, in addition to being low on fiber-
249 degraders, have elevated levels of harmful pathogenic bacteria, which is an important
250 consideration both for patient selections for clinical trials and for treating the individuals. As for
251 probiotics on the market, most are composed of “beneficial” species of *Bifidobacteria* and/or
252 *Lactobacillus*, which ironically, are highly elevated in PD. The value of the biomarker in this case
253 is to avoid supplementation that is counter indicated. FMT is showing promise for PD [28], but it
254 carries risks concerning safety and compatibility of donor sample with host environment. Using
255 biomarkers, unnecessary FMT can be avoided, sparing the patients who do not have a dysbiotic
256 microbiome and those whose only problem is low fiber-degraders. Targeted treatments could
257 replace the need for FMT, and they too would benefit from a companion diagnostic. For

258 example, for a treatment targeted to abolish the opportunistic pathogens, the biomarker can
259 identify the 13% of patients who would be the best candidates.
260
261 Currently, we do not know if alleviating one dysbiotic feature would restore homeostasis to the
262 rest of the microbiome, and what that central feature might be. Consumption of fiber is the
263 safest and simplest treatment. In a clinical trial performed on 20 newly diagnosed PD patients,
264 treatment with fiber increased the abundance of fiber-degrading bacteria and production of short
265 chain fatty acids and resulted in shifts in the microbiome community [27]. Fiber-degrading species
266 are in the center of the Firework with tight positive and negative correlations to several PD-
267 associated species (**Figure 2**). It is therefore plausible that fiber treatment, aimed to increase
268 the abundance of fiber-degrading bacteria, may restore equilibrium to PD-associated species
269 that map to the center of Firework and are either positively or negatively correlated with fiber-
270 degraders. However, while possible, it is less likely that fiber treatment alone would eliminate
271 overabundance of opportunistic pathogens, for example, considering that opportunistic
272 pathogens are a dense isolated cluster with no connection to fiber-degrading species.
273
274 Profiling the patients' metagenome and comparing them to the reference dataset will show
275 where they fall in the spectrum of dysbiosis. This concept, and the proposed method, holds true
276 regardless of feature, disease, or dataset. However, the relative abundances of the features and
277 therefore the range and thresholds for defining dysbiosis may differ across populations. Hence,
278 it is important that the reference dataset is from the same source population as patients. Here,
279 we used a cohort of neurologically healthy older adults from Birmingham, Alabama in United
280 States for our reference dataset, as our patients are also from Birmingham. There are regional
281 variation in microbiome, reflecting cultural, dietary, socioeconomic, and geographic influences.
282 Despite regional variations, the main PD-associated features are robust and reproducible [9-11,32].
283 Even so, the relative abundances, and hence the thresholds for defining dysbiosis, may still vary
284 across populations. Not every investigator can amass hundreds of controls to investigate
285 population-specific abundances to set their thresholds. This impediment will be overcome soon
286 by current efforts to collect all data generated and made public. These collaborative global
287 efforts are aimed at meta-analyses, a by-product of which will be open-access to well-curated
288 datasets from across the world that can be used as reference datasets to generate population-
289 specific thresholds for biomarkers and companion diagnostics.
290
291 **Data availability**

The datasets used for biomarker development are openly public with no restrictions [https://www.nature.com/articles/s41467-022-34667-x]. The raw metagenomic sequences and accompanying metadata are at the NCBI SRA under BioProject ID PRJNA834801 [https://www.ncbi.nlm.nih.gov/bioproject/834801], and post-QC and post taxonomic profiling data are on Zenodo [https://zenodo.org/record/7246185].

Acknowledgements

This work was supported by The Strain Endowed Chair in Parkinson's Disease to the University of Alabama at Birmingham (HP) and Aligning Science Across Parkinson's [ASAP-020527] through the Michael J. Fox Foundation for Parkinson's Research (MJFF) (HP, TRS, CFM). For the purpose of open access, the authors have applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funding agencies.

Author contribution

This is a collaborative team (genomics (HP), microbiology (TRS), statistics (CFM)). The lead/corresponding author (HP) conceptualized and developed the method. HP drafted the manuscript and all authors contributed to revision and approved the final version.

Competing interest

HP has intellectual property pending on Personalized Microbiome-Based Therapies, Serial No.: 63/571,787; Filing Date: March 29, 2024. TRS is a co-inventor on intellectual property related to a small molecule microbiome-based therapy - US Patent 11,707,493 and 11,147, 792.

References

1 Collaborators, G. B. D. P. s. D. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* **17**, 939-953 (2018). https://doi.org:10.1016/S1474-4422(18)30295-3

2 Obeso, J. A. *et al.* Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. *Mov Disord* **32**, 1264-1310 (2017). https://doi.org:10.1002/mds.27115

3 Braak, H., Rub, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J Neural Transm (Vienna)* **110**, 517-536 (2003). https://doi.org:10.1007/s00702-002-0808-2

4 Horsager, J. *et al.* Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* **143**, 3077-3088 (2020). https://doi.org:10.1093/brain/awaa238

5 Holmqvist, S. *et al.* Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. *Acta Neuropathol* **128**, 805-820 (2014). https://doi.org:10.1007/s00401-014-1343-6

6 Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end? *Mov Disord* **34**, 307-316 (2019). https://doi.org:10.1002/mds.27556

7 Kim, S. *et al.* Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron* **103**, 627-641 e627 (2019). https://doi.org:10.1016/j.neuron.2019.05.035

8 Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol* **19**, 55-71 (2021). https://doi.org:10.1038/s41579-020-0433-9

9 Wallen, Z. D. *et al.* Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms. *Nat Commun* **13**, 6958 (2022). https://doi.org:10.1038/s41467-022-34667-x

10 Romano, S. *et al.* Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. *NPJ Parkinsons Dis* **7**, 27 (2021). https://doi.org:10.1038/s41531-021-00156-z

11 Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-analysis. *Parkinsonism Relat Disord* **94**, 1-9 (2022). https://doi.org:10.1016/j.parkreldis.2021.11.017

12 Chen, S. G. *et al.* Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. *Sci Rep* **6**, 34477 (2016). https://doi.org:10.1038/srep34477

13 Sampson, T. R. *et al.* A gut bacterial amyloid promotes alpha-synuclein aggregation and motor impairment in mice. *Elife* **9** (2020). https://doi.org:10.7554/eLife.53111

14 Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell* **167**, 1469-1480 e1412 (2016). https://doi.org:10.1016/j.cell.2016.11.018

359 15 Matheoud, D. *et al.* Intestinal infection triggers Parkinson's disease-like symptoms in
360 Pink1(-/-) mice. *Nature* **571**, 565-569 (2019). https://doi.org:10.1038/s41586-019-1405-y
361 16 Radisavljevic, N. *et al.* Effects of Gut Microbiota Alterations on Motor, Gastrointestinal,
362 and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. *J Parkinsons Dis*
363 **12**, 1479-1495 (2022). https://doi.org:10.3233/JPD-223165
364 17 Bhattarai, Y. *et al.* Role of gut microbiota in regulating gastrointestinal dysfunction and
365 motor symptoms in a mouse model of Parkinson's disease. *Gut Microbes* **13**, 1866974
366 (2021). https://doi.org:10.1080/19490976.2020.1866974
367 18 Sun, M. F. *et al.* Neuroprotective effects of fecal microbiota transplantation on MPTP-
368 induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha
369 signaling pathway. *Brain Behav Immun* **70**, 48-60 (2018).
370 https://doi.org:10.1016/j.bbi.2018.02.005
371 19 Zhao, Z. *et al.* Fecal microbiota transplantation protects rotenone-induced Parkinson's
372 disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4
373 signaling pathway through the microbiota-gut-brain axis. *Microbiome* **9**, 226 (2021).
374 https://doi.org:10.1186/s40168-021-01107-9
375 20 Bisht, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral
376 oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
377 *Neurotoxicology* **44**, 71-79 (2014). https://doi.org:10.1016/j.neuro.2014.05.009
378 21 Du, Y. *et al.* Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the
379 MPTP model of Parkinson's disease. *Proc Natl Acad Sci U S A* **98**, 14669-14674 (2001).
380 https://doi.org:10.1073/pnas.251341998
381 22 Pu, Y. *et al.* Antibiotic-induced microbiome depletion protects against MPTP-induced
382 dopaminergic neurotoxicity in the brain. *Aging (Albany NY)* **11**, 6915-6929 (2019).
383 https://doi.org:10.18632/aging.102221
384 23 Kaur, B. & Prakash, A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation
385 and restores BDNF in MPTP model of Parkinson's disease in rats. *Pathophysiology* **24**,
386 71-79 (2017). https://doi.org:10.1016/j.pathophys.2017.02.001
387 24 Abdel-Haq, R. *et al.* A prebiotic diet modulates microglial states and motor deficits in
388 alpha-synuclein overexpressing mice. *Elife* **11** (2022).
389 https://doi.org:10.7554/eLife.81453
390 25 Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. *Nat Rev Microbiol* **20**,
391 365-380 (2022). https://doi.org:10.1038/s41579-021-00667-9

392 26 Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease -
393 from basic research to the clinic. *Nat Rev Neurol* **18**, 476-495 (2022).
394 https://doi.org:10.1038/s41582-022-00681-2
395 27 Hall, D. A. *et al.* An open label, non-randomized study assessing a prebiotic fiber
396 intervention in a small cohort of Parkinson's disease participants. *Nat Commun* **14**, 926
397 (2023). https://doi.org:10.1038/s41467-023-36497-x
398 28 DuPont, H. L. *et al.* Fecal microbiota transplantation in Parkinson's disease-A
399 randomized repeat-dose, placebo-controlled clinical pilot study. *Front Neurol* **14**,
400 1104759 (2023). https://doi.org:10.3389/fneur.2023.1104759
401 29 Cheng, Y. *et al.* Efficacy of fecal microbiota transplantation in patients with Parkinson's
402 disease: clinical trial results from a randomized, placebo-controlled design. *Gut Microbes*
403 **15**, 2284247 (2023). https://doi.org:10.1080/19490976.2023.2284247
404 30 Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota
405 transplant as a potential treatment for Parkinson's disease - A case series. *Clin Neurol*
406 *Neurosurg* **207**, 106791 (2021). https://doi.org:10.1016/j.clineuro.2021.106791
407 31 Xue, L. J. *et al.* Fecal microbiota transplantation therapy for Parkinson's disease: A
408 preliminary study. *Medicine (Baltimore)* **99**, e22035 (2020).
409 https://doi.org:10.1097/MD.0000000000022035
410 32 Wallen, Z. D. *et al.* Characterizing dysbiosis of gut microbiome in PD: evidence for
411 overabundance of opportunistic pathogens. *NPJ Parkinsons Dis* **6**, 11 (2020).
412 https://doi.org:10.1038/s41531-020-0112-6
413

Table 1. Six main dysbiotic features of PD gut microbiome

Feature	Species composition of feature	PD association	Number of connections
Opp pathogens	*Actinomyces turicensis*	Increased as cluster	8
Opp pathogens	*Anaerococcus octavius*	Increased as cluster	4
Opp pathogens	*Anaerococcus vaginalis*	Increased as cluster	5
Opp pathogens	*Atopobium minutum*	Increased as cluster	8
Opp pathogens	*Corynebacterium amycolatum*	Increased as cluster	2
Opp pathogens	*Corynebacterium aurimucosum*	Increased as cluster	2
Opp pathogens	*Finegoldia magna*	Increased as cluster	7
Opp pathogens	*Gemella asaccharolytica*	Increased as cluster	2
Opp pathogens	*Peptoniphilus harei*	Increased as cluster	1
Opp pathogens	*Peptoniphilus lacrimalis*	Increased as cluster	3
Opp pathogens	*Peptoniphilus sp HMSC062D09*	Increased as cluster	7
Opp pathogens	*Porphyromonas asaccharolytica*	Increased	6
Opp pathogens	*Porphyromonas sp HMSC065F10*	Increased as cluster	11
Opp pathogens	*Porphyromonas uenonis*	Increased as cluster	6
Opp pathogens	*Prevotella bergensis*	Increased as cluster	1
Opp pathogens	*Prevotella buccalis*	Increased as cluster	10
Opp pathogens	*Prevotella disiens*	Increased as cluster	1
Opp pathogens	*Prevotella timonensis*	Increased as cluster	8
Opp pathogens	*Varibaculum cambriense*	Increased as cluster	10
Bifidobacteria	*Bifidobacterium dentium*	Increased	12
Bifidobacteria	*Bifidobacterium bifidum*	Increased	3
Bifidobacteria	*Bifidobacterium breve*	Increased	24
Bifidobacteria	*Bifidobacterium gallinarum*	Increased	14
Bifidobacteria	*Bifidobacterium longum*	Increased	5
Bifidobacteria	*Bifidobacterium pullorum*	Increased	12
Bifidobacteria	*Bifidobacterium saeculare*	Increased	13
Lactobacillus	*Lactobacillus fermentum*	Increased	14
Lactobacillus	*Lactobacillus gasseri*	Increased	10
Lactobacillus	*Lactobacillus paragasseri*	Increased	9
Lactobacillus	*Lactobacillus salivarius*	Increased	9
Lactobacillus	*Lactobacillus reuteri*	Increased	1
Lactobacillus	*Lactobacillus rhamnosus*	Increased	11
Strepto / Actino	*Actinomyces naeslundii*	Increased	4
Strepto / Actino	*Actinomyces oris*	Increased	16
Strepto / Actino	*Actinomyces sp HPA0247*	Increased	3
Strepto / Actino	*Actinomyces sp oral taxon 448*	Increased	3
Strepto / Actino	*Streptococcus anginosus group*	Increased	10

Strepto / Actino	*Streptococcus mutans*	Increased	13
Strepto / Actino	*Streptococcus vestibularis*	Increased	15
Strepto / Actino	*Streptococcus lutetiensis*	Increased	3
E. coli / klebsiella	*Escherichia coli*	Increased	5
E. coli / klebsiella	*Klebsiella pneumoniae*	Increased	3
E. coli / klebsiella	*Klebsiella quasipneumoniae*	Increased	3
Fiber-degraders	*Blautia wexlerae*	Decreased	17
Fiber-degraders	*Blautia hansenii*	Decreased	17
Fiber-degraders	*Anaerostipes hadrus*	Decreased	48
Fiber-degraders	*Clostridium sp CAG 58*	Decreased	27
Fiber-degraders	*Eubacterium eligens*	Decreased	47
Fiber-degraders	*Eubacterium hallii*	Decreased	52
Fiber-degraders	*Eubacterium ramulus*	Decreased	25
Fiber-degraders	*Eubacterium rectale*	Decreased	21
Fiber-degraders	*Eubacterium sp CAG 38*	Decreased	22
Fiber-degraders	*Faecalibacterium prausnitzii*	Decreased	59
Fiber-degraders	*Fusicatenibacter saccharivorans*	Decreased	45
Fiber-degraders	*Roseburia faecis*	Decreased	21
Fiber-degraders	*Roseburia intestinalis*	Decreased	21
Fiber-degraders	*Roseburia inulinivorans*	Decreased	27
Fiber-degraders	*Ruminococcus bicirculans*	Decreased	33
Fiber-degraders	*Ruminococcus lactaris*	Decreased	12

We selected species that individually, or as a cluster, were significantly elevated or reduced in PD [9], and assigned them to a “feature” according to the correlation in their abundances (connectivity, see **Figure 2**) and their taxonomic relatedness (members of same genus). Here, our aim was to demonstrate the method, for which we strived for a balance between capturing the most robust association with PD and reducing the complexity. Features can be redefined to accommodate the aims of the investigation.

Table 2. **Defining dysbiotic**

Feature	Relative abundance of feature in 234 NHC			Relative abundance of feature in 490 PD			N PD outside 95% CI of NHC
	Mean	Upper 95% CI	Lower 95% CI	Mean	Upper 95% CI	Lower 95% CI	
Opp. pathogens	0.01%	**0.01%**	0.00%	0.10%	0.20%	0.00%	66
Bifidobacteria	2.06%	**2.66%**	1.47%	5.07%	5.98%	4.17%	161
Lactobacillus	0.11%	**0.19%**	0.04%	0.55%	0.74%	0.36%	103
Streptococcus / Actinomyces	0.19%	**0.33%**	0.06%	0.39%	0.54%	0.25%	94
E. coli / Klebsiella	1.47%	**2.23%**	0.72%	1.94%	2.44%	1.43%	86
Fiber-degraders	22.35%	23.88%	**20.81%**	15.29%	16.36%	14.22%	333

Each feature is composed of several species, as shown in **Table 1**. The relative abundance of each species in each individual was calculated as reported before [9] and can be found here https://zenodo.org/record/7246185. We calculated relative abundance of each feature in each neurologically healthy control (NHC) and individual with PD by summing the relative abundances of the species within the feature for that individual. We then calculated the mean and 95% confidence interval (CI) of the mean in the NHC and PD separately. We set the threshold for defining dysbiotic at the upper 95% CI of NHC for features that are elevated in PD, and at lower 95% CI of NHC for fiber-degraders that are reduced in PD. Last column is the number of PD patients, among 490 total, who were called dysbiotic for each feature. For example, in 161 of 490 PD patients, the relative abundance of *Bifidobacteria* was higher than 2.66% which was the upper 95% CI limit of NHC. Similarly, in 333 of 490 patients, the relative abundance of fiber-degrading bacteria was lower than 20.81% which was the lower 95% CI limit in NHC.

Building the reference dataset

No Disease

Sample collection for microbial DNA extraction

Metagenomic sequencing



Taxonomic assignment

Relative abundance of species (columns) per individual (rows)



Kingdom | Phylum | Class | Order | Family | Genus | Species

Relative abundances
Range, mean
95% CI in
No Disease population

compare

Application





Relative abundances



Figure 1. The method.

The concept is to develop a biomarker tool that will help us "see" if a person's microbiome is dysbiotic, and if so, what are their dysbiotic features. The goal is to optimize patient selection for clinical trials of microbiome-based studies, and upon approval, use it as diagnostic companion for personalized treatment. A reference dataset is built by obtaining the metagenomic profiles of a non-disease cohort that represents the same population as the persons to be studied or treated. Once this infrastructure is in place, one can pick any feature (from a microbial gene to species to polymicrobial clusters), calculate its relative abundance and confidence interval (CI) in the non-disease group, and set thresholds for defining dysbiotic and non-dysbiotic. Application entails obtaining the metagenomic profile of the individual of interest and comparing it to the non-disease population. Here, we selected 6 PD-associated features (each a polymicrobial cluster), 5 of which are elevated in PD, and one reduced in PD [9]. We set the threshold at 95%CI of the non-disease reference dataset. A person would be marked as dysbiotic for a feature if their relative abundance of that feature is above (for features that are elevated in PD) or below (for feature that are reduced) the 95%CI in non-disease population.



Figure 2. Fireworks

Polymicrobial clusters of species in PD gut microbiome. Pairwise correlation in relative abundances of all species detected in 490 unique PD gut metagenomes (i.e. 490 individuals with PD) was calculated and plotted (methods are described in Wallen et al [9]). Each circle (node) represents one species and the curved lines (edges) connect species whose relative abundance correlate with each other (at correlation $|r|>0.2$, permuted $P<0.05$). Here, we have highlighted PD-associated species that were selected for this study, denoting by color the 6 dysbiotic features (species within each feature are listed in **Table 1**):

Blue: Opportunistic pathogens (elevated in PD)

Red: fiber-degraders (reduced in PD)

Yellow: *E. coli* and *Klebsiella* (elevated in PD)

Green: *Bifidobacteria* (elevated in PD)

Orange: *Lactobacillus* (elevated in PD)

Purple: *Streptococcus* and *Actinomyces* (elevated in PD)

Grey: associated with PD, not selected as feature

Empty circle: not associated with PD

a



b

	Opp path	*Bifido-bacteria*	*Lacto-bacillus*	*Strepto /Actino*	*E. coli / Klebsiella*	Fiber-degraders
Opp Pathogens	66					
Bifidobacteria	33	161				
Lactobacillus	15	49	103			
Strepto / Actino	18	50	47	94		
E. coli/ Klebsiella	13	27	27	22	86	
Fiber-Degraders	57	135	88	81	69	333
No Others	5	18	5	5	9	96

c



Figure 3. Subtyping PD by the dysbiotic features of the gut microbiome.

The total number of patients is 490. The total number of patients with a dysbiotic feature is 392 (=490-98). The number of patients with a given dysbiotic feature are given in a-c. Actual numbers are given so that percentages can be calculated with the desired denominator.

(a) Proportion of PD patients with different dysbiotic features.

- Elevated features: number of PD persons, among the 490, who had an abundance higher than upper limit of the 95% CI of the abundance in neurologically healthy control (NHC).
- Reduced feature: number of PD persons, among the 490, who had an abundance lower than the lower limit of 95% CI of the abundance in NHC.
- No detectable dysbiosis: 98 of 490 (20%) did not fall outside 95% CI of NHC for any feature. 76 of 490 (16%) of PD persons fit the more cautious definition of non-dysbiotic, whose abundances for every elevated feature (opportunistic pathogens, *Bifidobacteria*, *Lactobacillus*, *Streptococcus* and *Actinomyces* (Strepto/Actino), and *E. coli/Klebsiella*) was below the NHC mean, and their abundance for reduced fiber-degrading bacteria was above the NHC mean.

(b) Pairwise overlap in features, n=number of patients, from 490, who have the two specified features. The total for six features (the diagonal) is 843, nearly double the number of 490 subjects, because features do co-occur in an individual. For example, 66 of 490 subjects had elevated (>95%CI of NHC) levels of opportunistic pathogens, among them, 33 (50%) also had elevated Bifidobacteria. Or the example in the text, 71% (=(333-96)/333) of low fiber-degraders had high level of at least one other feature.

(c) Overlap across the 5 features that are elevated in PD (fiber-reducers not included for legibility). For example, 19 subjects have elevated levels (>95%CI of NHC) of *Streptococcus* and *Actinomyces* only, another 2 subjects have high *Streptococcus* and *Actinomyces* and high opportunistic pathogens, another 3 have high *Streptococcus* and *Actinomyces,* high opportunistic pathogens, and high *Lactobacillus*, etc.